Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients

被引：24

作者：

Nakamura, Yasuhiro ^{[1
,27
]}

Namikawa, Kenjiro ^{[2
]}

Kiniwa, Yukiko ^{[3
]}

Kato, Hiroshi ^{[4
]}

Yamasaki, Osamu ^{[5
]}

Yoshikawa, Shusuke ^{[6
]}

Maekawa, Takeo ^{[7
]}

Matsushita, Shigeto ^{[8
]}

Takenouchi, Tatsuya ^{[9
]}

Inozume, Takashi ^{[10
]}

Nakai, Yasuo ^{[11
]}

Fukushima, Satoshi ^{[12
]}

Saito, Shintaro ^{[13
]}

Otsuka, Atsushi ^{[14
,15
]}

Fujimoto, Noriki ^{[16
]}

Isei, Taiki ^{[17
]}

Baba, Natsuki ^{[18
]}

Matsuya, Taisuke ^{[19
]}

Tanaka, Ryo ^{[20
]}

Kaneko, Takahide ^{[21
]}

Onishi, Masazumi ^{[22
]}

Kuwatsuka, Yutaka ^{[23
]}

Nagase, Kotaro ^{[24
]}

Onuma, Takehiro ^{[25
]}

Nomura, Motoo ^{[26
]}

Umeda, Yoshiyasu ^{[1
,20
]}

Yamazaki, Naoya ^{[2
]}

机构：

[1] Saitama Med Univ, Dept Skin Oncol Dermatol, Int Med Ctr, Saitama, Japan

[2] Natl Canc Ctr, Dept Dermatol Oncol, Tokyo, Japan

[3] Shinshu Univ, Dept Dermatol, Matsumoto, Japan

[4] Nagoya City Univ, Dept Geriatr & Environm Dermatol, Grad Sch Med Sci, Nagoya, Japan

[5] Okayama Univ, Dept Dermatol, Dent & Pharmaceut Sci, Grad Sch Med, Okayama, Japan

[6] Shizuoka Canc Ctr, Dermatol Div, Shizuoka, Japan

[7] Jichi Med Univ, Dept Dermatol, Tochigi, Japan

[8] Natl Hosp Org, Dept Dermato Oncol Dermatol, Kagoshima Med Ctr, Kagoshima, Japan

[9] Niigata Canc Ctr Hosp, Dept Dermatol, Niigata, Japan

[10] Chiba Univ, Dept Dermatol, Chiba, Japan

[11] Mie Univ, Dept Dermatol, Mie, Japan

[12] Kumamoto Univ, Fac Life Sci, Dept Dermatol & Plast Surg, Kumamoto, Japan

[13] Gunma Univ, Dept Dermatol, Grad Sch Med, Maebashi, Japan

[14] Kyoto Univ, Dept Dermatol, Kyoto, Japan

[15] Kindai Univ Hosp, Dept Dermatol, Osaka, Japan

[16] Shiga Univ Med Sci, Dept Dermatol, Otsu, Japan

[17] Osaka Int Canc Inst, Dept Dermatol Oncol, Osaka, Japan

[18] Univ Fukui, Dept Dermatol, Fukui, Japan

[19] Asahikawa Med Univ, Dept Dermatol, Asahikawa, Japan

[20] Kawasaki Med Sch, Dept Dermatol, Kurashiki, Japan

[21] Juntendo Univ, Dept Dermatol, Urayasu Hosp, Chiba, Japan

[22] Iwate Med Univ, Dept Dermatol, Iwate, Japan

[23] Nagasaki Univ, Dept Dermatol, Nagasaki, Japan

[24] Saga Univ, Fac Med, Dept Internal Med, Div Dermatol, Saga, Japan

[25] Univ Yamanashi, Dept Dermatol, Yamanashi, Japan

[26] Kyoto Univ, Dept Clin Oncol, Kyoto, Japan

[27] Saitama Med Univ, Dept Skin Oncol Dermatol, Int Med Ctr, 1397-1 Yamane, Saitama 3501298, Japan

来源：

EUROPEAN JOURNAL OF CANCER | 2022年 / 176卷

关键词：

CTLA-4; antigen; Immunotherapy; Ipilimumab; Melanoma; Nivolumab; Pembrolizumab; Programmed cell death 1 receptor; Retrospective studies; Japan; SINGLE-ARM; OPEN-LABEL; PD-1; BLOCKADE; PHASE-II; MUCOSAL; IPILIMUMAB; INHIBITORS; NIVOLUMAB; MUTATION; SAFETY;

D O I：

10.1016/j.ejca.2022.08.030

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Although anti-PD-1 antibody monotherapy (PD-1) is commonly used to treat advanced acral melanoma (AM), its efficacy is limited. Further, data on the efficacy of PD-1 plus anti-CTLA-4 antibody (PD-1+CTLA-4) for the treatment of AM are limited. Therefore, we compared the efficacy of PD-1+CTLA-4 and PD-1 in the treatment of Japanese patients with advanced AM. Methods: This retrospective study evaluated patients with advanced AM who were treated with PD-1 or PD-1+CTLA-4 as first-line immunotherapy in 24 Japanese institutions between 2014 and 2020. Treatment efficacy focussing on the objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) was compared between the two groups. Results: In total, 254 patients (palm and sole melanoma [PSM], n = 180; nail apparatus melanoma [NAM], n = 74) were included. Among the patients with PSM, the ORR (19% vs. 31%; P = 0.44), PFS (5.9 vs. 3.2 months; P = 0.74), and OS (23.1 vs. not reached; P = 0.55) did not differ significantly between the PD-1 and PD-1+CTLA-4 groups. Among the patients with NAM, the ORR (61% vs. 10%; P < 0.001) was significantly higher and PFS was longer (6.4 vs. 3.8 months; P = 0.10) in the PD-1+CTLA-4 group than in the PD-1 group. Cox multivariate analysis demonstrated that PD-1+CTLA-4 is an independent predictor of a favourable PFS in patients with NAM (P = 0.002). Conclusions: The efficacy of PD-1+CTLA-4 is not superior to that of PD-1 for the treatment of advanced PSM. However, PD-1+CTLA-4 may be more efficacious than PD-1 for the treatment of advanced NAM. (C) 2022 Elsevier Ltd. All rights reserved.

引用

页码：78 / 87

页数：10

共 50 条

[1] Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study)
Nakamura, Y.
Namikawa, K.
Yoshikawa, S.
Kiniwa, Y.
Maekawa, T.
Yamasaki, O.
Isei, T.
Matsushita, S.
Nomura, M.
Nakai, Y.
Fukushima, S.
Saito, S.
Takenouchi, T.
Tanaka, R.
Kato, H.
Otsuka, A.
Matsuya, T.
Baba, N.
Nagase, K.
Inozume, T.
Fujimoto, N.
Kuwatsuka, Y.
Onishi, M.
Kaneko, T.
Onuma, T.
Umeda, Y.
Ogata, D.
Takahashi, A.
Otsuka, M.
Teramoto, Y.
Yamazaki, N.
ESMO OPEN, 2021, 6 (06)
[2] Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
Bhave, Prachi
Ahmed, Tasnia
Lo, Serigne N.
Shoushtari, Alexander
Zaremba, Anne
Versluis, Judith M.
Mangana, Joanna
Weichenthal, Michael
Si, Lu
Lesimple, Thierry
Robert, Caroline
Trojanello, Claudia
Wicky, Alexandre
Heywood, Richard
Tran, Lena
Batty, Kathleen
Dimitriou, Florentia
Stansfeld, Anna
Allayous, Clara
Schwarze, Julia K.
Mooradian, Meghan J.
Klein, Oliver
Mehmi, Inderjit
Roberts-Thomson, Rachel
Maurichi, Andrea
Yeoh, Hui-Ling
Khattak, Adnan
Zimmer, Lisa
Blank, Christian U.
Ramelyte, Egle
Kaehler, Katharina C.
Roy, Severine
Ascierto, Paolo A.
Michielin, Olivier
Lorigan, Paul C.
Johnson, Douglas B.
Plummer, Ruth
Lebbe, Celeste
Neyns, Bart
Sullivan, Ryan
Hamid, Omid
Santinami, Mario
McArthur, Grant A.
Haydon, Andrew M.
Long, Georgina, V
Menzies, Alexander M.
Carlino, Matteo S.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (07)
[3] Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study
Umeda, Yoshiyasu
Yoshikawa, Shusuke
Kiniwa, Yukiko
Maekawa, Takeo
Yamasaki, Osamu
Isei, Taiki
Matsushita, Shigeto
Nomura, Motoo
Nakai, Yasuo
Fukushima, Satoshi
Saito, Shintaro
Takenouchi, Tatsuya
Tanaka, Ryo
Kato, Hiroshi
Otsuka, Atsushi
Matsuya, Taisuke
Baba, Natsuki
Nagase, Kotaro
Inozume, Takashi
Onuma, Takehiro
Kuwatsuka, Yutaka
Fujimoto, Noriki
Kaneko, Takahide
Onishi, Masazumi
Namikawa, Kenjiro
Yamazaki, Naoya
Nakamura, Yasuhiro
EUROPEAN JOURNAL OF CANCER, 2021, 157 : 361 - 372
[4] Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials
Hao, Chunyan
Tian, Jinhui
Liu, Huiling
Li, Fei
Niu, Hongxia
Zhu, Bingdong
MEDICINE, 2017, 96 (26)
[5] Comparison of efficacy between anti-PD-1 antibody monotherapy and nivolumab plus ipilimumab therapy as first-line immunotherapy for advanced mucosal melanoma in Japanese patients: A single-center, retrospective cohort study
Horisaki, Ken
Yoshikawa, Shusuke
Omata, Wataru
Tsutsumida, Arata
Kiyohara, Yoshio
JOURNAL OF DERMATOLOGY, 2024, 51 (11) : 1425 - 1433
[6] Seasonal patterns of toxicity in melanoma patients treated with combination anti-PD-1 and anti-CTLA-4 immunotherapy
Rogiers, Aljosja
Dimitriou, Florentia
Lobon, Irene
Harvey, Catriona
Vergara, Ismael A.
da Silva, Ines Pires
Lo, Serigne N.
Scolyer, Richard A.
Carlino, Matteo S.
Menzies, Alexander M.
Long, Georgina V.
EUROPEAN JOURNAL OF CANCER, 2024, 198
[7] Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases
da Silva, Ines Pires
Li, Isabel
Ugurel, Selma
Serra-Bellver, Patricio
Andhale, Avanti
Burnette, Hannah
Aya, Francisco
Conway, Jordan W.
Braden, Jorja
Carlino, Matteo S.
Menzies, Alexander M.
Weichenthal, Michael
Mohr, Peter
Gutzmer, Ralf
Arance, Ana M.
Johnson, Douglas B.
Lorigan, Paul
Schadendorf, Dirk
Lo, Serigne N.
Long, Georgina V.
EUROPEAN JOURNAL OF CANCER, 2024, 205
[8] Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
Bowyer, S.
Prithviraj, P.
Lorigan, P.
Larkin, J.
McArthur, G.
Atkinson, V.
Millward, M.
Khou, M.
Diem, S.
Ramanujam, S.
Kong, B.
Liniker, E.
Guminski, A.
Parente, P.
Andrews, M. C.
Parakh, S.
Cebon, J.
Long, G. V.
Carlino, M. S.
Klein, O.
BRITISH JOURNAL OF CANCER, 2016, 114 (10) : 1084 - 1089
[9] Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma
Reddy, Swathi B.
Possick, Jennifer D.
Kluger, Harriet M.
Galan, Anjela
Han, Dale
JOURNAL OF IMMUNOTHERAPY, 2017, 40 (08) : 307 - 311
[10] Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
Afzal, Muhammad Zubair
Mabaera, Rodwell
Shirai, Keisuke
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6

← 1 2 3 4 5 →